Nurix Therapeutics, Inc.
H-1B Sponsorship & Salary Data — Government-Verified
$139,904Avg. Salary
17Filings
17+Job Titles
December 2025Last Filing
According to TheRealSalaries.com analysis of official US Department of Labor filings (October 2024 - December 2025), Nurix Therapeutics, Inc. pays a median H-1B salary of $140,000 — 15% above the national median of $121,514, ranking in the top 23% of 13,957 ranked H-1B sponsors. Based on 17 certified Labor Condition Applications.
Section 1
What does Nurix Therapeutics, Inc. pay?
Nurix Therapeutics, Inc.'s H-1B filings show an average salary of $139,904 based on 17 certified LCA applications. Salaries range from $87,360 to $225,000.
$139,904
Average
$140,000
Median
$87,360
Minimum
$225,000
Maximum
Recent H-1B Filings
| Job Title | Salary |
|---|---|
| Associate Director, Clinical Data Management | $225,000 |
| Medicinal Chemistry Contractor | $87,360 |
| Research Associate II, Preclinical Pharmacology | $113,000 |
| Scientist II “ Cell Biology | $115,000 |
| Senior Research Associate, Cell Screening | $115,000 |
| Scientist II, Discovery Biology | $140,000 |
| Scientist II - Formulations | $140,000 |
| Research Associate III, Cell Screening | $115,000 |
| Bioinformatics, Scientist I | $140,000 |
| Associate Director, Chemical Development | $170,000 |
| Scientist II, Medicinal Chemistry | $153,000 |
| Associate Director, Pharmaceutical Development | $140,000 |
| Senior Research Associate, Nurix Adoptive Cell Therapy | $115,000 |
| Senior Manager, Head of Developmental Bioanalytical | $165,000 |
| Senior Scientist, Discovery Biology | $140,000 |
| Associate Director, Pharmacovigilance QMS and Compliance | $140,000 |
| Associate Director, Pharmacovigilance Scientist | $165,000 |
Section 2
States with Nurix Therapeutics, Inc. H-1B Filings
Similar Companies
Section 3
All salaries above must meet the Department of Labor's wage floor — see how the H-1B prevailing wage levels work, or browse all sponsor companies.
Source: US Department of Labor LCA Disclosure Data. Last updated: Q1 FY2025.